Florida homeowners say between soaring fees and sky-high insurance, state condo reform ‘too little, too late'
'I've seen my condo HOAs at $450, double in two years to $900, and I've seen thousands of dollars in assessments. That's what it's cost us,' Sullivan, a condo owner in St. Petersburg, told ABC Action News.
Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast)
Nervous about the stock market in 2025? Find out how you can access this $1B private real estate fund (with as little as $10)
Across Florida, thousands of condo owners are facing similar financial pressures as homeowner association (HOA) fees and insurance premiums skyrocket.
The 2021 Surfside condominium collapse, which claimed 98 lives, prompted Florida lawmakers to enact sweeping safety regulations.
The disaster exposed widespread structural vulnerabilities in the state's aging condo buildings.
The resulting legislation requires milestone inspections and structural integrity reserve studies for condos 30 years or older and three stories high, as well as strict funding requirements for future repairs.
The compliance deadline — Dec. 31, 2024 — triggered fee hikes and surprise assessments. Some owners, like Sullivan, have already paid thousands for repairs with little warning.
'A lot of people here were financially strapped for doing this, myself included,' said fellow condo owner Tyler Clee.
'To come up and say, I need $10,000 in three months — for most of us, that's not realistic.'
The financial fallout is chilling Florida's condo market. Listings in areas like Pinellas County have been sitting on the market longer, ABC Action News reports, as buyers balk at unpredictable costs.
Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it
In response to mounting pressure, lawmakers passed House Bill 913 — the latest revision to the post-Surfside condo reform. While core safety rules remain intact, the bill includes key concessions:
A one-year delay in funding structural integrity reserve deadlines.
Permission for associations to use loans or lines of credit instead of cash.
Clarification from inspectors on which repairs are safety-related.
The bill also allows electronic voting to engage more owners in financial decisions. For many residents, the changes come too late. Sullivan's building has already set its budget and has completed major repairs based on the earlier deadlines.
'It's too little, too late,' she said.
'I was hoping they would have done that before the end of last year, because we were forced into a position, because of the timeline, that we had to take care of all of that. … Now, I'm not sure if other condos could be helpful to them, that's great. It's not for us.'
Instead, residents hope for zero- or low-interest loans to offset assessments that weren't included.
While the new law offers short-term relief, many say broader reform is needed. One of the biggest frustrations is that the legislation does little to address soaring condo insurance.
Experts and residents alike suggest more balanced, long-term strategies. These could include:
Phased timelines. Allow condo associations to resolve urgent repairs first and offer extended deadlines for less critical upgrades. That way, owners have time to plan, save and avoid sudden, unaffordable assessments.
Means-tested aid. State-backed grants or low-interest loans to seniors and low-to-moderate-income residents to help cover extensive assessments or emergency repairs.
Tax incentive. Provide tax credits or deductions for unit owners or associations making qualified repairs — such as structural reinforcements, roofing or waterproofing.
Exemptions or relaxed rules. Exempt or reduce requirements for small, low-rise or recently constructed condos with clean inspection records.
As Florida's condo communities grapple with the financial fallout of much-needed reforms, many hope lawmakers will allow sustainable recovery. The goal being to ensure staying safe doesn't mean losing your home or going into debt.
Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead
How much cash do you plan to keep on hand after you retire? Here are 3 of the biggest reasons you'll need a substantial stash of savings in retirement
Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now
Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you?
Like what you read? Join 200,000+ readers and get the best of Moneywise straight to your inbox every week.
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Europe's Billionaires Are Bending to Trump--Here's Why Investors Should Pay Attention
With Donald Trump's July 9 tariff deadline approaching, pressure is mountingnot just in Brussels, but in boardrooms across Europe. Automakers like Mercedes-Benz (MBGAF), BMW (BMWKY), and Volkswagen (VWAGY) have been quietly flying executives to Washington, lobbying U.S. officials directly and proposing their own peace terms to head off a potential 50% tariff on European exports. Luxury powerhouses like LVMH (LVMUY) and pharmaceutical giants like Sanofi have joined in, signaling a clear shift: many of Europe's biggest companies are no longer aligned with the EU's hardline approach. Behind the scenes, they're urging Brussels to cut a quick deal and scale back retaliatory measures, including removing high-profile U.S. products like bourbon from any counter-tariff list. Warning! GuruFocus has detected 4 Warning Sign with MBGAF. What's driving this sudden corporate detente? Profitsand survival. European companies generate wide margins in the U.S. and rely heavily on American technology, suppliers, and research partnerships. A retaliatory tariff packageinitially floated at 95 billionhas already been softened by member state requests that could slash it by nearly 70 billion. Lobby groups representing sectors from medical devices to spirits warn that hitting back at the U.S. would hurt European firms just as much, if not more. If the EU retaliates, the sector is hit twice, said MedTech Europe CEO Oliver Bisazza. That fear has flipped the script, with industries now pressing Brussels to de-escalate, even if it means swallowing a flat 10% tariff and lobbying for carve-outs in key sectors like pharma, semiconductors, and aerospace. But this fractured front comes at a delicate time for the EU. With domestic demand weakening, China gaining ground, and energy costs still elevated post-Ukraine, the U.S. market is more important than ever. Brussels wants to preserve unity, but member states are growing impatient. German Chancellor Friedrich Merz has openly criticized the Commission's slow, complex process and called for speed over perfection. LVMH Chairman Bernard Arnault has gone furtheractivating long-standing ties with Trump and making personal trips to Washington to promote a calmer path. His message? In this geopolitical chess match, compromise could be the smartest move Europe has left. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
What Makes Mondelez International (MDLZ) an Attractive Investment?
Lindsell Train Ltd, an investment management company, has released its "Lindsell Train Global Equity Fund" first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The objective of the fund is to boost long-term Shareholders' capital from an actively managed global equity portfolio, mainly on recognized exchanges in developed countries worldwide. The fund returned -2.0% in the quarter, outperforming the -4.7% return for the benchmark MSCI World Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2025. In its first-quarter 2025 investor letter, Lindsell Train Global Equity Fund highlighted stocks such as Mondelez International, Inc. (NASDAQ:MDLZ). Mondelez International, Inc. (NASDAQ:MDLZ) manufactures and markets snack food and beverage products. The one-month return of Mondelez International, Inc. (NASDAQ:MDLZ) was 4.40%, and its shares gained 4.85% of their value over the last 52 weeks. On July 2, 2025, Mondelez International, Inc. (NASDAQ:MDLZ) stock closed at $69.56 per share, with a market capitalization of $90.068 billion. Lindsell Train Global Equity Fund stated the following regarding Mondelez International, Inc. (NASDAQ:MDLZ) in its Q1 2025 investor letter: "Heineken and Mondelez International, Inc. (NASDAQ:MDLZ) also possess strong defensive qualities, because they sell low ticket, frequently-purchased items, protected by brand power built up over decades of cumulative advertising spend. One can see clear evidence of the consumer loyalty they enjoy via their resilient volume growth figures over the last few years, despite the considerable price increases they've been obliged to pass through in the post-Covid inflationary period." A colourful array of products like candies, chocolates and gums on a supermarket shelf. Mondelez International, Inc. (NASDAQ:MDLZ) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held Mondelez International, Inc. (NASDAQ:MDLZ) at the end of the first quarter, which was 55 in the previous quarter. While we acknowledge the potential of Mondelez International, Inc. (NASDAQ:MDLZ) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Mondelez International, Inc. (NASDAQ:MDLZ) and shared top stock picks for an early retirement portfolio. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of MDLZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Wire
2 days ago
- Business Wire
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year
SYDNEY--(BUSINESS WIRE)--In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. Share Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. 'Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for small to mid-size biotech, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials.' — Unmesh Lal, Vice President – Healthcare & Life Sciences, Frost & Sullivan According to Frost & Sullivan, Novotech's client-first approach, coupled with its scale and scientific capabilities, continues to set it apart in the biotech CRO space. The firm's deep therapeutic expertise in oncology, rare diseases, infectious diseases, and advanced modalities—such as gene therapies and RNA-based treatments—was cited as a key differentiator. The award also acknowledged Novotech's ability to maintain trial continuity and delivery excellence amid geopolitical, operational, and economic volatility. Strategic use of AI-enabled tools, predictive analytics, and real-time data platforms further enables Novotech to accelerate timelines and improve decision-making for biotech sponsors. 'We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide.' — Dr. John Moller, CEO, Novotech Unmesh Lal added: 'Frost & Sullivan believes Novotech's road ahead is about growing without losing its soul: scaling globally while staying deeply connected to biotech clients, preserving its cultural DNA, and delivering the high-touch, high-value service that has become its hallmark.' The award was accepted on behalf of Novotech by Scott Schliebner, Vice President of Drug Development Consulting, during the Frost & Sullivan Excellence in Best Practices Awards Gala held in Los Angeles, California, on June 26. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit